logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Nussara Pakvisal

Mass General Brigham
H指数:5
被引数:76

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors

微卫星稳定型转移性结直肠癌患者接受免疫检查点抑制剂治疗后，肝转移对生存的影响

Cancer Research Communications
IF0
2026-02-010
OA
Pakvisal, Nussara; Pappas, Leontios; Caughey, Bennett A.; Horick, Nora K.; Tarazona, Noelia; Vora, Kruti B.; Ouyang, Ben; Pandey, Aditya; Peacker, Bryan L.; Sun, Joie; Zubiri, Leyre; Reynolds, Kerry L.; Ryan, David P.; Qadan, Motaz; Corcoran, Ryan B.; Giantonio, Bruce; Allen, Jill N.; Walsh, Elizabeth P.; Clark, Jefferey W.; Ting, David T.; Parikh, Aparna R.
Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study

阿替利珠单抗联合贝伐珠单抗以及伦伐替尼作为肝细胞癌一线系统性疗法的安全性和有效性：一项真实世界研究

PLoS One
IF2.6
2025-12-180
PRE
Boonkaya, Sangdao; Pattarawongpaiboon, Chidkamon; Thaimai, Panarat; Ananchuensook, Prooksa; Sriphoosanaphan, Supachaya; Tanasanvimon, Suebpong; Teeyapun, Nattaya; Pakvisal, Nussara; Siripon, Nipaporn; Treeprasertsuk, Sombat; Komolmit, Piyawat; Thanapirom, Kessarin
Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer

一线与后续抗表皮生长因子受体疗法在不切除、RAS/BRAF野生型、左侧转移性结直肠癌中的总生存期

WORLD JOURNAL OF CLINICAL ONCOLOGY
IF3.2
2025-03-240
PRE
Pakvisal, Nussara; Goldberg, Richard M.; Sathitruangsak, Chirawadee; Silaphong, Witthaya; Faengmon, Satawat; Teeyapun, Nattaya; Teerapakpinyo, Chinachote; Tanasanvimon, Suebpong
Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients

放射治疗患者中同源和异源腺病毒载体和mRNA新型冠状病毒肺炎疫苗方案的安全性和免疫原性

VACCINES
IF3.4
2023-06-231
OAAI
Prayongrat, Anussara; Noppaving, Patjaya; Chobarporn, Thitiporn; Sudhinaraset, Natthinee; Teeyapun, Nattaya; Pakvisal, Nussara; Jantarabenjakul, Watsamon; Sophonphan, Jiratchaya; Lertbutsayanukul, Chawalit; Poovorawan, Yong
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

与先前接种ChAdOx1或CoronaVac的实体癌患者的mRNA-1273相比，使用BNT162b2新型冠状病毒肺炎加强疫苗后的安全性

VACCINES
IF3.4
2023-02-030
OAAI
Wanchaijiraboon, Passakorn; Sainamthip, Panot; Teeyapun, Nattaya; Luangdilok, Sutima; Poovorawan, Yong; Wanlapakorn, Nasamon; Tanasanvimon, Suebpong; Sriuranpong, Virote; Susiriwatananont, Thiti; Zungsontiporn, Nicha; Pakvisal, Nussara
Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
JCO GLOBAL ONCOLOGY
IF3
2022-12-0110
OAAI
Charonpongsuntorn, Chanchai; Tanasanvimon, Suebpong; Korphaisarn, Krittiya; Payapwattanawong, Songwit; Siripoon, Teerada; Pakvisal, Nussara; Juengsamarn, Jitlada; Phaibulvatanapong, Ekkamol; Chindaprasirt, Jarin; Prasongsook, Naiyarat; Udomdamrongkul, Kittipong; Ngamphaiboon, Nuttapong; Sirachainan, Ekaphop
Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
ECLINICALMEDICINE
IF10
2022-10-018
OAAI
Teeyapun, Nattaya; Luangdilok, Sutima; Pakvisal, Nussara; Sainamthip, Panot; Mingmalairak, Siyamol; Poovorawan, Nattaya; Sitthideatphaiboon, Piyada; Parinyanitikul, Napa; Sriuranpong, Virote; Namkanisorn, Teerayuth; Inthasuwan, Pratchaya; Angspatt, Pattama; Wongchanapat, Ploytuangporn; Bamrungnam, Akradach; Leeleakpai, Nutchanok; Uttha, Sutheera; Jaichum, Supaporn; Kongkaew, Peerawich; Suksanong, Chayanin; Veranitinun, Rattiya; Prasomphol, Ampai; Sartsuk, Chada; Patcharajutanon, Cheeraporn; Preaprang, Supreeya; Choengsamor, Hathairat; Phongwan, Rungthong; Preeyasaksa, Charoenpit; Phaibulvatanapong, Ekkamol; Suntronwong, Nungruthai; Yorsaeng, Ritthideach; Vichaiwattana, Preeyaporn; Wanlapakorn, Nasamon; Kerr, Stephen J.; Poovorawan, Yong; Wanchaijiraboon, Passakorn; Tanasanvimon, Suebpong
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

先前接受过初级异源CoronaVac/ChAdOx1疫苗的实体癌患者第三次新型冠状病毒肺炎mRNA加强后的免疫原性

VACCINES
IF3.4
2022-09-268
OAAI
Luangdilok, Sutima; Wanchaijiraboon, Passakorn; Pakvisal, Nussara; Susiriwatananont, Thiti; Zungsontiporn, Nicha; Sriuranpong, Virote; Sainamthip, Panot; Suntronwong, Nungruthai; Vichaiwattana, Preeyaporn; Wanlapakorn, Nasamon; Poovorawan, Yong; Teeyapun, Nattaya; Tanasanvimon, Suebpong
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
HUMAN VACCINES & IMMUNOTHERAPEUTICS
IF3.5
2022-07-014
OAAI
Pakvisal, Nussara; Sainamthip, Panot; Teeyapun, Nattaya; Luangdilok, Sutima; Wanlapakorn, Nassamon; Yorsaeng, Ritthideach; Poovorawan, Yong; Pakvisal, Piyapoom; Susiriwatananont, Thiti; Zungsontiporn, Nicha; Sriuranpong, Virote; Tanasanvimon, Suebpong; Wanchaijiraboon, Passakorn

研究方向

暂未获取到该数据
S
Suebpong Tanasanvimon
H 指数:17论文数:108被引数:3,439
N
Nattaya Teeyapun
H 指数:5论文数:24被引数:64
Y
Yong Poovorawan
H 指数:64论文数:977被引数:2.2万
P
Panot Sainamthip
H 指数:6论文数:27被引数:92
S
Sutima Luangdilok
H 指数:8论文数:35被引数:278
P
Passakorn Wanchaijiraboon
H 指数:4论文数:21被引数:74
T
Thiti Susiriwatananont
H 指数:4论文数:23被引数:47
N
Nasamon Wanlapakorn
H 指数:29论文数:173被引数:2,896
N
Nicha Zungsontiporn
H 指数:4论文数:33被引数:51
E
Ekkamol Phaibulvatanapong
H 指数:3论文数:5被引数:49